AbbVie and Neurocrine Biosciences have reported positive results from a Phase IIb clinical trial of elagolix to minimise menstrual bleeding in women with uterine fibroids.

Elagolix is an orally administered, short-acting molecule being developed to block endogenous gonadotropin-releasing hormone (GnRH) signalling.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The trial results showed that 300mg elagolix met the primary efficacy endpoint by decreasing heavy menstrual bleeding.

The 24-week, multi-centre, double-blind, randomised, placebo-controlled, parallel group Phase II M12-813 trial assessed the efficacy and safety of elagolix alone or in combination with estradiol / norethindrone acetate add-back therapy compared to placebo.

The trial was performed in 567 pre-menopausal women aged 18-51 at 100 sites in the US, Canada, Puerto Rico, Chile and the UK.

See Also:

AbbVie chief medical officer and development vice-president Rob Scott said: "Current non-surgical treatments indicated for uterine fibroids are limited, and women suffering from heavy menstrual bleeding associated with uterine fibroids need more options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Current non-surgical treatments indicated for uterine fibroids are limited, and women suffering from heavy menstrual bleeding associated with uterine fibroids need more options."

"The positive results from this clinical trial represent a significant milestone in the development of elagolix, support AbbVie's ongoing Phase III uterine fibroids research and demonstrate our continued commitment to address complex and serious diseases."

The primary endpoint of the trial is to measure the change in menstrual blood loss at month six using the alkaline hematin method.

A significant decrease in the number of heavy bleeding days and increase in the haemoglobin concentration were observed at month six.

It was found that elagolix was well-tolerated, minimised symptom severity and improved quality of life.

The firm's Phase III uterine fibroids programme includes study of elagolix under two replicate, six-month efficacy and safety trials and a six-month safety and efficacy extension study.